Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kyra A. Toomey
Observed names:
Kyra A Toomey,
Kyra Toomey,
Toomey, Kyra A
Institutions:
VA Northern California Health Care System,
University of California Davis Medical Center,
UC Davis Comprehensive Cancer Center,
University of California, Davis
Observed institutions:
VA Northern California Health Care System,
University of California Davis Medical Center,
UC Davis Comprehensive Cancer Center,
University of California, Davis
ORCID:
0000-0002-1758-3527
Observed ORCID:
0000-0002-1758-3527
OpenAlex ID:
A5036407587
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives
2023
·
Luis A. Godoy
, Joy Chen
, et al.
·
Biomarker Research
·
72
PDF
Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma
2020
·
Jun Gong
, Jeremy Chuang
, et al.
·
International Journal of Molecular Sciences
·
14
PDF
Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC
2021
·
Weijie Ma
, Jie Zeng
, et al.
·
Biomarker Research
·
9
PDF
Labyrinthin Expression Is Associated with Poor Prognosis in Patients with Non-Small-Cell Lung Cancer
2023
·
Weijie Ma
, Jie Zeng
, et al.
·
Cancers
·
5
PDF
Immunotherapy in synchronous MSI-H rectal adenocarcinoma and upper tract urothelial carcinoma: a case report
2022
·
Jacqueline Hsieh-Wong
, James Liu
, et al.
·
Journal of Gastrointestinal Oncology
·
3
PDF
1140 Labyrinthin as a potential neoantigen for oncogene-driven and non-oncogene-driven lung adenocarcinomas
2023
·
Dennis J Montoya
, Siqi Long
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
632 A phase 1/2 open label study of LabVax 3(22)-23 and adjuvant GM-CSF alone or in combination with pembrolizumab in subjects with labyrinthin-positive adenocarcinomas
2023
·
Tianhong Li
, Shuai Chen
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Real world early experience of precision neoadjuvant systemic therapy in patients with resectable NSCLC: Single institution experiences and perspectives.
2023
·
Cathleen Park
, Kyra Toomey
, et al.
·
Journal of Clinical Oncology
PDF
A first-in-human phase I trial of a novel peptide vaccine LabVax 3(22)-23 and adjuvant GM-CSF sargramostim in patients with refractory labyrinthin-expressing adenocarcinomas.
2023
·
Tianhong Li
, Shuai Chen
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
10
Citation count:
108
H-index:
4
I10-index:
2
Year
Topic
Type